# OnCo record lifileucel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/lifileucel/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "lifileucel" ;
  schema:name "Lifileucel"@en ;
  schema:description "Lifileucel was the first approved TIL therapy: the patient's own tumour-fighting immune cells are expanded to billions and given back."@en ;
  schema:url <https://onco.cc/drugs/lifileucel/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Lifileucel> ;
  owl:sameAs <http://www.wikidata.org/entity/Q107400406> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lifileucel> ;
  onco:status "approved" ;
  onco:modality "TIL cell therapy" ;
  schema:alternateName "Amtagvi" ;
  onco:approval "US 2024: Unresectable/metastatic melanoma after anti-PD-1 (and BRAF/MEK if applicable)" ;
  onco:acceleratedApproval "US 2024-02-16: Adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor." ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/til-therapy/> ;
  onco:companies <https://onco.cc/companies/iovance/> ;
  onco:trials <https://onco.cc/trials/nct07288203/>, <https://onco.cc/trials/nct06481592/> ;
  onco:people <https://onco.cc/people/inge-marie-svane/> .